EQS-News: Bio-Gate AG signs LOI with North American medical device manufacturer for trauma implants
EQS-News: Bio-Gate AG
/ Key word(s): Incoming Orders/Letter of Intent
Bio-Gate AG signs LOI with North American medical device manufacturer for trauma implants
31.07.2023 / 17:01 CET/CEST
The issuer is solely responsible for the content of this announcement.
PRESS INFORMATION
Bio-Gate AG signs LOI with North American medical device manufacturer for trauma implants
Nuremberg/Bremen, July 31, 2023 - Bio-Gate AG (ISIN DE000BGAG981), a leading provider of innovative technologies and individual solutions for health and hygiene, has concluded a preliminary agreement (LOI, Letter-of-Intent) with a North American medical device manufacturer focusing on the trauma sector. The medical device manufacturer intends to use Bio-Gate's "HyProtectTM" coating process for its own implants in human medicine following the FDA approval process.
With the North American medical device manufacturer, Bio-Gate has gained another important company as a partner for its "HyProtect" coating technology and can develop significant growth potential in applications for human medicine in the future. The repeatedly documented interest in Bio-Gate’s „HyProtect“ coating is a strong evidence of the high relevance of the technology.
Bio-Gate uses the "HyProtect" technology to coat medical devices with an ultra-thin layer containing polysiloxane and silver. The release of silver ions provides an antibacterial effect without altering product properties such as biocompatibility or biomechanical behavior. The infection data on the use of "HyProtect" is very positive, especially for implants in individual cases in human medicine and also for serial production implants in veterinary medicine.
Investor Relations
Bio-Gate AG / Gerd Rückel
Neumeyerstr. 28-34
D-90411 Nürnberg
[email protected]
Tel. +49 (0) 911 477523-444
Mobil +49 (0)152 34221966
Press
Bio-Gate AG
Neumeyerstr. 28-34
D-90411 Nürnberg
[email protected]
Tel. +49 (0) 911 477523-222
About Bio-Gate AG
Bio-Gate AG is a medical technology company that develops and markets applications which use unique silver technology to help prevent infections and thus to improve health. Bio-Gate AG’s specialty is using pure silver to treat materials and surfaces that are used in all areas of daily life – thus providing long-term and medically effective protection against bacteria, microorganisms and other pathogens. Bio-Gate AG works in three fields to supply a variety of products that provide antimicrobial protection: material enhancement, surface coatings and testing the antimicrobial or anti-adhesive properties of materials. The Nuremberg-based company offers systems that stretch across the entire value chain, from development to approval to production. For more information, please visit www.bio-gate.de.
Disclaimer
This publication constitutes neither an offer to sell nor an invitation to buy securities. The shares in Bio-Gate AG (the “Shares”) may not be offered or sold in the United States or to or for the account or benefit of “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”)). The securities have already been sold.
31.07.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
|
Language: |
English |
Company: |
Bio-Gate AG |
|
Neumeyerstr. 28-34 |
|
90411 Nürnberg |
|
Germany |
Phone: |
+49 (0) 911 / 47 75 23 – 100 |
Fax: |
+49 (0) 911 / 47 75 23 – 101 |
E-mail: |
[email protected] |
Internet: |
www.bio-gate.de |
ISIN: |
DE000BGAG981 |
WKN: |
BGAG98 |
Listed: |
Regulated Unofficial Market in Berlin, Frankfurt, Munich (m:access), Stuttgart |
EQS News ID: |
1692375 |
|
End of News |
EQS News Service |
1692375 31.07.2023 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
3,83 |
3,69 |
3,49 |
5,13 |
6,24 |
5,90 |
7,25 |
EBITDA1,2 |
0,05 |
-0,64 |
-0,75 |
-0,52 |
-0,35 |
-1,55 |
-1,33 |
EBITDA-Marge3 |
1,31 |
-17,34 |
-21,49 |
-10,14 |
-5,61 |
-26,27 |
|
EBIT1,4 |
-0,19 |
-0,89 |
-1,05 |
-0,82 |
-0,54 |
-1,79 |
-1,59 |
EBIT-Marge5 |
-4,96 |
-24,12 |
-30,09 |
-15,98 |
-8,65 |
-30,34 |
-21,93 |
Jahresüberschuss1 |
-0,18 |
-0,87 |
-1,03 |
-0,80 |
-0,56 |
-1,81 |
-1,62 |
Netto-Marge6 |
-4,70 |
-23,58 |
-29,51 |
-15,59 |
-8,97 |
-30,68 |
-22,35 |
Cashflow1,7 |
-0,11 |
-0,57 |
-1,01 |
-0,60 |
-0,63 |
-2,16 |
-0,98 |
Ergebnis je Aktie8 |
-0,03 |
-0,14 |
-0,16 |
-0,11 |
-0,07 |
-0,22 |
-0,19 |
Dividende8 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. ![](/wp-content/uploads/assets/icon/pdf_24x24.png)
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Rödl & Partner
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Bio-Gate |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
BGAG98 |
0,985 |
Halten |
9,11 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
0,00 |
0,00 |
0,00 |
-9,56 |
KBV |
KCV |
KUV |
EV/EBITDA |
2,64 |
- |
1,26 |
-5,86 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,00 |
0,00 |
0,00 |
14.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
|
29.08.2024 |
|
30.04.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-2,96% |
-4,37% |
-11,26% |
-15,81% |
|
|